An Open-Label, Multicenter, Extension Study for Patients Previously Enrolled in Studies With Pelabresib

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508950-24-00

Acronym

CDAK539A12001B

Enrollment

Registered

2024-08-29

Start date

2024-10-01

Completion date

Unknown

Last updated

2026-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myelofibrosis, Myeloproliferative Neoplasms (Myelofibrosis and Essential Thrombocythemia)

Brief summary

Occurrence and severity of treatment-emergent adverse events (TEAEs) and serious TEAEs among patients who are receiving pelabresib, Survival and leukemia-free survival, Time-to-event endpoints (eg, duration of response, progression-free survival)

Interventions

DRUGCPI-0610

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Occurrence and severity of treatment-emergent adverse events (TEAEs) and serious TEAEs among patients who are receiving pelabresib, Survival and leukemia-free survival, Time-to-event endpoints (eg, duration of response, progression-free survival)	—

Countries

Belgium, Italy, Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026